Mesoblast (MESO) said late Wednesday it received seven years of orphan drug exclusivity from the US Food and Drug Administration for Ryoncil, a treatment approved for steroid-refractory acute graft versus host disease in children aged two months and older.
The company said the exclusivity means that the US health agency can not approve any mesenchymal stromal or stem cell products for the same use during this period.
Additionally, the company said Ryoncil has 12 years of biologic exclusivity, blocking biosimilar competition until December 2036.
The statutory protections add to Mesoblast's US patents position on MSC composition of matter, manufacturing, and indications that provide a commercial barrier to entry against competitors through 2044, it added.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。